American Cancer Society and Stand Up To Cancer announce lung cancer “Dream Team”
The American Cancer Society and Stand Up To Cancer (SU2C) have announced a new $20 million Lung Cancer “Dream Team,” comprising prominent researchers from eight leading institutions, focused on lung cancers with a mutation in a gene called “KRAS” (k-rass).
KRAS, or K-RAS, is a gene that, when mutated, might cause cancer or help it to grow. This is not an inherited mutation; it’s a spontaneous mutation that starts in a single cell, which then grows and multiplies.
KRAS mutations are common in lung cancers, but difficult to treat. The Dream Team brings together the unique specialties of targeted therapy and immunotherapy to devise a completely new approach.